
Focused on solving unmet needs in ophthalmology
Our pipeline of topical drug candidates promises improvement in drug delivery for the back- and front-of-the-eye

Changing the paradigm in DME
Developing non-invasive therapy for DME, a leading cause of blindness

Taking a new approach in managing dry eye disease
The potential to be the first topical biologic for ophthalmic use

Simplifying treatment for post-cataract surgery inflammation
The potential for fewer daily drops and improved compliance

Disruptive new technologies for ophthalmic topical treatment
Enabling new topical options for patients with eye diseases